A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)

被引：0
|
作者：
Rugo, H.
Tolaney, S.
Dickler, M.
Kabos, P.
Ho, C-L
Wildiers, H.
Jerusalem, G.
Ales-Martinez, J. E.
Hossain, A.
Johnston, E.
Gianni, L.
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Univ Colorado, Anschutz Med Campus, Aurora, CO USA
[5] Tri Serv Gen Hosp, Natl Def Med Ctr, Taipei, Taiwan
[6] Univ Ziekenhuis Leuven Gasthuisbert, Leuven, Belgium
[7] Univ Sart Tilman, Ctr Hospitalier, Liege, Belgium
[8] Hosp Nuestra Senora Sonsoles, Complejo Hospitalario Avila Oncol, Avila, Spain
[9] Eli Lilly & Co, Indianapolis, IN 46285 USA
[10] IRCCS Osped, Milan, Italy
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-OT2-01-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-01-07
引用
收藏
页数：2
相关论文
共 50 条
  • [41] nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2-advanced breast cancer
    Hamilton, E.
    Cortes, J.
    Dieras, V.
    Ozyilkan, O.
    Chen, S-C
    Petrakova, K.
    Manikhas, A.
    Jerusalem, G.
    Hegg, R.
    Lu, Y.
    Bear, M. M.
    Johnston, E. L.
    Martin, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [42] General Characteristics, Patterns of Relapse and Treatment Outcomes of Patients with HER2 Amplified Metastatic Breast Cancer (MBC) who are Hormone Receptor Positive (HR plus ) Versus Hormone Receptor Negative (HR-)
    Dumbrava, Monica I.
    De Boer, Richard
    Lok, Sheau
    Gibbs, Peter
    Greenberg, Sally
    Pellegrini, Laura
    Yip, Desmond
    Malik, Laeeq
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 119 - 120
  • [43] Abemaciclib pharmacology and interactions in the treatment of HR+/HER2- breast cancer: a critical review
    Martorana, Federica
    Sano, Maria Vita
    Valerio, Maria Rosaria
    Fogli, Stefano
    Vigneri, Paolo
    Danesi, Romano
    Gebbia, Vittorio
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2024, 15
  • [44] A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer (BC; plus /- endocrine therapy), or non-small-cell lung cancer (NSCLC)
    Yee, D.
    Prat, A.
    Sablin, M. P.
    Iwata, H.
    Johnston, E. L.
    Bogenrieder, T.
    Serra, J.
    Hua, H.
    LoRusso, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] A Phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours, hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer (BC; plus /-endocrine therapy), or non-small-cell lung cancer (NSCLC)
    Prat, A.
    Yee, D.
    Sablin, M. P.
    Iwata, H.
    Johnston, E. L.
    Bogenrieder, T.
    Serra, J.
    Stucke-Straub, K.
    Lo Russo, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] Effect of cyclin-dependent kinase 4 and 6 inhibitors (CDKIs) on body composition (BC) in patients (pts) with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
    Phuong, Lisa
    Patel, Janki
    Baka, Nadia
    Goldman, Jessica
    Lyudmer, Michael
    Shamir, Stephanie
    Deng, Junwen
    Soto, Alvaro Alvarez
    Anampa Mesias, Jesus Del Santo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients
    Wang, Jinhao
    Liu, Yaxin
    Liang, Yuehua
    Zhang, Yue
    Dong, Hang
    Zheng, Tiantian
    Yu, Jianjun
    Du, Pan
    Jia, Shidong
    King, Bonnie L. L.
    Wang, Jing
    Liu, Xiaoran
    Li, Huiping
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [48] Impact of gene expression profile testing for lymph node positive (LN plus ), hormone receptor positive (HR+), HER2 negative (HER2-) breast cancer (BC) patients on the use of adjuvant chemotherapy in a large community cancer center
    Kalmadi, Nisha Rao
    Brown, Andrew
    Sharma, Manas
    Shtivelband, Mikhail
    Rifkind, Joshua
    Kalmadi, Sujith
    Bagai, Rajesh
    Ho, Emily
    Clark, Patricia
    Kellogg, Christopher
    Khanuja, Parvinderjit
    CANCER RESEARCH, 2022, 82 (04)
  • [49] Survival of metastatic hormone receptor (HR) positive/HER2 negative; HER2+; and triple negative (TN) breast cancer based on initial presentation
    den Brok, Wendie-Lou D.
    Speers, Caroline
    Lovedeep, Gondara
    Baxter, Emily
    Tyldesley, Scott
    Caroline, Lohrisch
    CANCER RESEARCH, 2015, 75
  • [50] A phase 2 study of abemaciclib in patients with leptomeningeal metastases secondary to HR+, HER2-breast cancer
    Tolaney, S. M.
    Sahebjam, S.
    Le Rhun, E.
    Lin, Nu
    Bear, M. Markel
    Yang, Z.
    Chen, Y.
    Anders, C. K.
    CANCER RESEARCH, 2019, 79 (04)
12345